fig1
![Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?](https://image.oaes.cc/777b1aec-4767-48e3-848e-0c11ee5b14c2/4081.fig.1.jpg)
Figure 1. (A) The ubiquitin-mediated protein degradation pathway. Proteins, polyubiquitinated by an enzyme complex containing a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin-protein ligase (E3), are recognized and degraded by the 26S proteasome. (B) Two main (or standard) 20S proteasome subtypes present in mammalian cells: the constitutive proteasome (cP) and immunoproteasome (iP).